| Start | 3 months | 15 months | 27 months | 39 months | 51 months | 63 months | 75 months | |
| Median per core set response variable (25%–75%): | ||||||||
| VAS doctor | 68 (53–78) | 15 (8–29) | 10 (2–23) | 10 (2–20) | 11 (4–32) | 5 (0–10) | 6 (0–14) | 10 (5–35) |
| CHAQ (0–3) | 2.0 (1.2–2.4) | 1.0 (0.4–1.8) | 0.4 (0–1.0) | 0.4 (0–1.0) | 0.8 (0.2–1.4) | 0.3 (0–0.9) | 0.6 (0.1–1.1) | 0.9 (0.5–1.6) |
| VAS well-being | 54 (27–76) | 10 (2–40) | 5 (0–26) | 8 (0–27) | 6 (0–45) | 10 (0–36) | 9 (0–59) | 30 (6–58) |
| Active joints | 12 (7–22) | 2 (0–6) | 1 (0–3) | 0 (0–6) | 1 (0–4) | 0 (0–2) | 0 (0–2) | 1 (0–5) |
| Limited joints | 9 (6–14) | 5 (2–9) | 2 (1–6) | 0 (0–6) | 4 (2–9) | 3 (2–5) | 3 (1–5) | 3 (2–7) |
| ESR (mm/h) | 27 (15–46) | 10 (5–20) | 8 (5–17) | 4 (1–7) | 11 (5–32) | 8 (4–16) | 7 (4–15) | 16 (5–33) |
| Patients per JIA subtype: | ||||||||
| Total population | n = 146 | n = 142 | n = 97 | n = 57 | n = 29 | n = 23 | n = 10 | n = 5 |
| ACR30 | 112 | 90 | 50 | 21 | 21 | 7 | 3 | |
| ACR50 | 95 | 88 | 46 | 19 | 21 | 7 | 3 | |
| ACR70 | 72 | 74 | 40 | 15 | 17 | 6 | 2 | |
| Remission | 35 | 27 | 9 | 11 | 5 | 1 | ||
| Systemic JIA | n = 39 | n = 37 | n = 24 | n = 16 | n = 9 | n = 8 | n = 4 | n = 0 |
| ACR30 | 22 | 21 | 14 | 6 | 8 | 4 | ||
| ACR50 | 16 | 20 | 13 | 6 | 8 | 4 | ||
| ACR70 | 10 | 16 | 10 | 5 | 7 | 4 | ||
| Remission | 9 | 8 | 5 | 7 | 4 | |||
| Polyarticular JIA RF+ | n = 11 | n = 11 | n = 9 | n = 5 | n = 4 | n = 4 | n = 3 | n = 3 |
| ACR30 | 9 | 8 | 3 | 3 | 3 | 1 | 2 | |
| ACR50 | 8 | 8 | 3 | 3 | 3 | 1 | 2 | |
| ACR70 | 6 | 7 | 2 | 2 | 2 | 1 | 1 | |
| Remission | 3 | 1 | 0 | 1 | 1 | 1 | ||
| Polyarticular JIA RF– | n = 55 | n = 53 | n = 36 | n = 24 | n = 10 | n = 8 | n = 2 | n = 1 |
| ACR30 | 48 | 33 | 21 | 8 | 7 | 1 | 0 | |
| ACR50 | 42 | 33 | 18 | 6 | 7 | 1 | 0 | |
| ACR70 | 33 | 28 | 17 | 5 | 6 | 1 | 0 | |
| Remission | 14 | 12 | 2 | 3 | 0 | 0 | ||
| Oligoarticular JIA | n = 28 | n = 28 | n = 18 | n = 9 | n = 3 | n = 2 | n = 1 | n = 1 |
| ACR30 | 22 | 18 | 9 | 1 | 2 | 1 | 1 | |
| ACR50 | 20 | 17 | 9 | 1 | 2 | 1 | 1 | |
| ACR70 | 16 | 15 | 8 | 1 | 1 | 0 | 0 | |
| Remission | 6 | 5 | 1 | 0 | 0 | 0 | ||
| ERA | n = 5 | n = 5 | n = 4 | n = 2 | n = 2 | n = 1 | n = 0 | n = 0 |
| ACR30 | 4 | 4 | 2 | 2 | 1 | |||
| ACR50 | 4 | 4 | 2 | 2 | 1 | |||
| ACR70 | 4 | 3 | 2 | 1 | 1 | |||
| Remission | 0 | 0 | 0 | 0 | ||||
| JIA psoriatica | n = 8 | n = 8 | n = 6 | n = 1 | n = 1 | n = 0 | n = 0 | n = 0 |
| ACR30 | 7 | 6 | 1 | 1 | ||||
| ACR50 | 5 | 6 | 1 | 1 | ||||
| ACR70 | 3 | 5 | 1 | 1 | ||||
| Remission | 3 | 1 | 1 | |||||
Data shown is n or n (range). ACR Pedi 30, 50, 70, American College of Rheumatology paediatric score for 30, 50 or 70% improvement.14 Remission: criteria of remission by Wallace et al on medication.15
CHAQ, children’s health assessment questionnaire; ERA, enthesitis-related arthritis; ESR, erythrocyte sedimentation rate; oJIA ext, oligoarticular extended JIA; pJIA RF–, polyarticular rheumatoid factor negative JIA; pJIA RF+, polyarticular rheumatoid factor positive JIA; PsJIA, juvenile arthritis psoriatica; sJIA, systemic JIA; VAS, visual analogue scale (0–100 mm).